256 related articles for article (PubMed ID: 19539742)
1. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
3. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease neuroimaging initiative in Europe.
Frisoni GB
Alzheimers Dement; 2010 May; 6(3):280-5. PubMed ID: 20451877
[TBL] [Abstract][Full Text] [Related]
5. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
Vos SJ; Visser PJ; Verhey FR
Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's CSF markers in older schizophrenia patients.
Frisoni GB; Prestia A; Geroldi C; Adorni A; Ghidoni R; Amicucci G; Bonetti M; Soricelli A; Rasser PE; Thompson PM; Giannakopoulos P
Int J Geriatr Psychiatry; 2011 Jun; 26(6):640-8. PubMed ID: 20872913
[TBL] [Abstract][Full Text] [Related]
7. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
Shoji M
Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
Zetterberg H; Blennow K
J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
10. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
11. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
15. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Vanderstichele H; Bibl M; Engelborghs S; Le Bastard N; Lewczuk P; Molinuevo JL; Parnetti L; Perret-Liaudet A; Shaw LM; Teunissen C; Wouters D; Blennow K
Alzheimers Dement; 2012 Jan; 8(1):65-73. PubMed ID: 22047631
[TBL] [Abstract][Full Text] [Related]
16. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
17. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.
Dumurgier J; Paquet C; Benisty S; Kiffel C; Lidy C; Mouton-Liger F; Chabriat H; Laplanche JL; Hugon J
Neurobiol Dis; 2010 Nov; 40(2):456-9. PubMed ID: 20656030
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
19. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
20. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
